Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials
Clinical Cardiology · 2026-06 · 49 (6)
DOI: 10.1002/clc.70391 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Cardiology, online erschienen am 23.06.2026. Verfasst von Rahul Falodia und 6 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, Jodhpur, India. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Baxdrostat is a selective aldosterone synthase (CYP11B2) inhibitor for treatment‐resistant and uncontrolled hypertension, evaluated in phase 2/3 RCTs.
Objectives
To estimate pooled placebo‐corrected reductions in seated office and ambulatory SBP, characterize the dose–response relationship, assess cortisol selectivity, and quantify hyperkalemia risk.
Methods
We conducted a systematic review and meta‐analysis of phase 2/3 randomized, double‐blind, placebo‐controlled trials of baxdrostat in hypertension, searching MEDLINE/PubMed, EMBASE, ClinicalTrials.gov, and NEJM.org to March 2026. The primary outcome was placebo‐corrected change in seated office SBP, analyzed using random‐effects meta‐analysis (REML) with metafor in R. Risk of bias and certainty were evaluated using Cochrane RoB 2.0 and GRADE, respectively.
Results
Three RCTs (BrigHTN, BaxHTN, Bax24; N = 1285) were included. The pooled seated SBP reduction was −9.44 mmHg (95% CI: −11.09 to −7.79; I 2 = 0.0%), with dose subgroup estimates of −8.57 mmHg (1 mg) and −10.11 mmHg (2 mg) and a clear dose–response in BrigHTN (slope −4.2 mmHg/mg; R 2 = 0.96). Bax24 demonstrated a 24 h ambulatory SBP reduction of −14.0 mmHg (95% CI: −17.2 to −10.8). Serum cortisol was unsuppressed at all doses, while the pooled OR for potassium ≥ 6.0 mmol/L was 5.14 (95% CI: 1.76 to 14.97). GRADE certainty was moderate for seated SBP, low to moderate for ambulatory outcomes, and low for hyperkalemia.
Conclusions
Baxdrostat produces meaningful, selective BP reductions across hypertensive populations. Hyperkalemia is manageable with structured monitoring. Certainty is limited by a few trials, a short follow‐up, and safety imprecision. Long‐term cardiovascular outcome data are needed before guideline incorporation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- All India Institute of Medical Sciences, Jodhpur, India.
- Faculty of Medicine, Kandahar University, Kandahar, Afghanistan.
- Saidu Medical College, Saidu Sharif, Swat, Pakistan.
- Neurosurgery Department, Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar.
- Dow University of Health Sciences, Karachi, Pakistan.
- White River Medical Center, Batesville, Arkansas, USA.
ORCID-Profile: Rahul Falodia, Ehsanullah Alokozay, Taha Alam
Zitieren
APA
Falodia, R., Alokozay, E., Idrees, M., Paghdar, D., Msheik, A., Alam, T., & Zadran, S. (2026). Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials. Clinical Cardiology, 49(6). https://doi.org/10.1002/clc.70391
Vancouver
Falodia R, Alokozay E, Idrees M, Paghdar D, Msheik A, Alam T, et al. Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials. Clinical Cardiology. 2026;49(6). doi:10.1002/clc.70391
BibTeX
@article{Falodia2026,
author = {Falodia, Rahul and Alokozay, Ehsanullah and Idrees, Mohammad and Paghdar, Darsh and Msheik, Ali and Alam, Taha and Zadran, Saeedullah},
title = {Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {6},
doi = {10.1002/clc.70391}
}
EUVIMED